VERV Stock Cash Flow Statements

Verve Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Verve Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30

cash flows from operating activities:
net income	-31,033,000	-50,035,000	-50,133,000	-49,805,000	-48,736,000	-48,352,000	-45,758,000	-53,983,000	-51,975,000	-41,085,000	-45,190,000	-40,946,000	-30,166,000	-31,337,000	-22,749,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	1,716,000	1,700,000	1,754,000	1,667,000	1,632,000	1,517,000	1,474,000	1,337,000	1,127,000	925,000	717,000	648,000	514,000	472,000	412,000
non-cash lease expense	1,865,000	1,839,000	1,815,000	1,791,000	1,768,000	1,746,000	1,725,000	1,689,000	1,632,000	1,628,000	1,280,000	500,000	499,000	497,000
net accretion of discount on marketable securities	-1,893,000	-2,155,000	-2,745,000
stock-based compensation	11,174,000	10,449,000	10,818,000	11,647,000	10,341,000	9,254,000	8,825,000	9,013,000	8,024,000	6,704,000	5,920,000	5,650,000	4,203,000	2,758,000	2,293,000
change in fair value of success payments liabilities	-223,000	205,000	6,000	-1,671,000	-78,000	713,000	-802,000	662,000	-738,000	-2,177,000	3,306,000	-938,000	-1,677,000	-1,139,000	-700,000
changes in operating assets and liabilities:
collaboration receivable	1,856,000	-626,000	410,000	2,686,000	168,000	-2,775,000				-83,000
prepaid expenses and other assets	2,117,000		-1,819,000	-4,274,000	-672,000		368,000	-2,006,000	-949,000		-6,474,000	-4,043,000	1,149,000		-5,508,000
accounts payable	729,000	491,000	-2,568,000	3,553,000	-3,306,000	4,499,000	-2,060,000	-14,000	1,485,000	1,195,000	-5,394,000	4,088,000	-5,105,000	3,485,000	2,061,000
accrued expenses and other liabilities	-7,515,000	2,460,000	2,257,000	3,559,000	-3,649,000	-3,227,000	3,545,000	1,734,000	-2,283,000	2,380,000	-515,000	8,307,000	-3,131,000	5,113,000	2,448,000
operating lease liabilities	-1,348,000	-1,272,000	-1,221,000	-1,198,000	-1,234,000	-1,900,000	-1,058,000	-2,698,000	-1,564,000	-170,000	-1,793,000	-525,000	-523,000	-521,000
deferred revenue	-5,290,000	-2,581,000	1,819,000	1,425,000	4,651,000	2,000				0
net cash from operating activities	-27,845,000	-40,845,000	-39,607,000	-34,158,000	-43,082,000	-40,680,000	-11,811,000	-47,962,000	-49,096,000	-32,892,000	-29,175,000	-26,758,000	-33,507,000	-28,043,000	-21,355,000
capex	-1,224,000	-1,387,000	-936,000	-980,000	-433,000	-2,185,000	-1,061,000	-2,662,000	-3,375,000	-4,968,000	-2,637,000	-2,719,000	-2,908,000	-981,000	-1,002,000
free cash flows	-29,069,000	-42,232,000	-40,543,000	-35,138,000	-43,515,000	-42,865,000	-12,872,000	-50,624,000	-52,471,000	-37,860,000	-31,812,000	-29,477,000	-36,415,000	-29,024,000	-22,357,000
cash flows from investing activities:
purchases of property and equipment	-1,224,000	-1,387,000	-936,000	-980,000	-433,000	-2,185,000	-1,061,000	-2,662,000	-3,375,000	-4,968,000	-2,637,000	-2,719,000	-2,908,000	-981,000	-1,002,000
purchases of marketable securities	-144,817,000	-73,067,000	-74,830,000	-111,908,000	-164,190,000	-122,323,000	-147,940,000	-113,122,000	-133,755,000	-257,323,000	-147,829,000			-137,004,000	-223,314,000
maturities of marketable securities	97,873,000	104,000,000	132,578,000	143,038,000	122,991,000	115,615,000	137,167,000	148,809,000	152,522,000	93,978,000	94,950,000	84,750,000	63,000,000	81,000,000	12,000,000
net cash from investing activities	-48,168,000	29,546,000	56,812,000	30,150,000	-41,632,000	-8,893,000	-11,834,000	33,025,000	15,392,000	-168,313,000	-55,516,000	7,782,000	60,092,000	-56,985,000	-212,316,000
cash flows from financing activities:
proceeds from issuance of common stock, net of issuance costs		24,301,000	0	-51,000	22,484,000			-65,000	1,987,000
proceeds from exercise of stock options	7,000	119,000	14,000	826,000	301,000	323,000	213,000	548,000	116,000	442,000	1,108,000	120,000	505,000	442,000	0
payment of equity offering costs					-51,000	-393,000				-178,000
net cash from financing activities	7,000	25,150,000	14,000	1,298,000	22,734,000	177,383,000	31,923,000	1,233,000	2,038,000	39,598,000	288,408,000	445,000	505,000	1,224,000	-867,000
decrease in cash, cash equivalents and restricted cash	-76,006,000		17,219,000	-2,710,000	-61,980,000
cash, cash equivalents and restricted cash—beginning of period	177,334,000	0	0	0	210,954,000	0	0	0	120,236,000	0	0	0	69,567,000	0	0
cash, cash equivalents and restricted cash—end of period	101,328,000	13,851,000	17,219,000	-2,710,000	148,974,000	127,810,000	8,278,000	-13,704,000	88,570,000	-161,607,000	203,717,000	-18,531,000	96,657,000	-83,804,000	-234,538,000
supplemental disclosure of noncash investing and financing activities:
property and equipment additions included in accounts payable and accrued expenses	396,000	-667,000	246,000	-34,000	545,000	1,039,000	-37,000	-1,125,000	1,657,000	-319,000	856,000	-848,000	2,017,000	142,000	-433,000
prepaid expenses and other current assets
cash flows from financing activities
proceeds from the issuance of common stock in connection with collaboration agreements						0
issuance of common stock under employee stock purchase plan		796,000	0				0
increase in cash, cash equivalents and restricted cash						127,810,000	8,278,000	-13,704,000	-31,666,000	-161,607,000	203,717,000	-18,531,000	27,090,000	-83,804,000	-234,538,000
financing costs included in accounts payable and accrued expenses
right-of-use assets obtained in exchange for new operating lease liabilities										2,173,000				0
net amortization of premium (accretion of discount) on marketable securities					-3,967,000	-3,338,000	-3,493,000	-3,696,000	-3,855,000
change in fair value of antidilution rights														0	0
success payment liability
proceeds from issuance of preferred stock														0	0
proceeds from purchase of shares through employee stock purchase plan
conversion of convertible preferred stock to common stock upon closing of initial public offering														0	0
settlement of derivative liability by issuing common stock
proceeds from issuance of common stock, net of commissions
offering costs included in accounts payable and accrued liabilities
payment of financing costs									-65,000
change in fair value of preferred stock tranche liabilities
deferred rent liability
proceeds from the issuance of common stock in connection with the vertex agreement										0
settlement of tranche right liability
amortization of premium on marketable securities											-117,000	501,000	730,000	740,000	412,000
proceeds from initial public offering, net of underwriting discount														0	0
proceeds from issuance of common shares, net of commissions
issuance of shares through employee stock purchase plan											0
settlement of antidilution rights liability by issuing common stock															0
proceeds from issuance of series b convertible preferred stock
payment of initial public offering costs														2,000	-867,000
initial public offering costs included in accounts payable and accrued liabilities
non-cash research and development license expense
shareholder loan given
payments received on shareholder loan
issuance of preferred stock tranche liability
cash and cash equivalents
restricted cash
total cash, cash equivalents and restricted cash

We provide you with 20 years of cash flow statements for Verve Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verve Therapeutics stock. Explore the full financial landscape of Verve Therapeutics stock with our expertly curated income statements.

The information provided in this report about Verve Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.